The isocitrate dehydrogenase (IDH) mutation status and methylation of the O-6-methylguanine-DNA methyltransferase (MGMT) gene promoter are established prognostic markers of GBM evaluated in patients’ tumor samples [1,4,5,6,7]. The gene discussed is MGMT; the disease is glioblastoma.